Asset Details
Do you wish to reserve the book?
Dose correction for post-contrast T1 mapping of the heart: the MESA study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dose correction for post-contrast T1 mapping of the heart: the MESA study
Do you wish to request the book?
Dose correction for post-contrast T1 mapping of the heart: the MESA study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dose correction for post-contrast T1 mapping of the heart: the MESA study
2016
Overview
Post-contrast myocardial T1 (T1
myo,c
) values have been shown to be sensitive to myocardial fibrosis. Recent studies have shown differences in results obtained from T1
myo,c
and extracellular volume fraction (ECV) with respect to percentage fibrosis. By exploring the relationship between blood plasma volume and T1
myo,c
, the underlying basis for the divergence can be explained. Furthermore, dose administration based on body mass index (BMI), age and gender can mitigate the divergence in results. Inter-subject comparison of T1
myo,c
required adjustment for dose (in mmol/kg), time and glomerular filtration rate. Further adjustment for effective dose based on lean muscle mass reflected by blood/plasma volume was performed. A test case of 605 subjects from the MESA study who had undergone pre- and post-contrast T1 mapping was studied. T1
myo,c
values were compared between subjects with and without metabolic syndrome (MetS), between smoking and non-smoking subjects, and subjects with and without impaired glucose tolerance, before and after dose adjustment based on plasma volume. Comparison with ECV (which is dose independent), pre-contrast myocardial T1 and blood normalized myocardial T1 values was also performed to validate the correction. There were significant differences in T1
myo,c
(post plasma volume correction) and ECV between current and former smokers (
p
value 0.017 and 0.01, respectively) but not T1
myo,c
prior to correction (
p
= 0.12). Prior to dose adjustment for plasma volume,
p
value was <0.001 for T1
myo,c
between MetS and non-MetS groups and was 0.13 between subjects with and without glucose intolerance; after adjustment for PV,
p
value was 0.63 and 0.99. Corresponding ECV
p
values were 0.44 and 0.99, respectively. Overall, ECV results showed the best agreement with PV corrected T1
myo,c
(mean absolute difference in
p
values = 0.073) and pre-contrast myocardial T1 in comparison with other measures (T1
myo,c
prior to correction, blood/plasma T1 value normalized myocardium). Weight-based contrast dosing administered in mmol/kg results in a bias in T1 values which can lead to erroneous conclusions. After adjustment for lean muscle mass based on plasma volume, results from T1
myo,c
were in line with ECV derived results. Furthermore, the use of a modified equivalent dose adjusted for BMI, age, sex and hematocrit can be adopted for quantitative imaging.
Publisher
Springer Netherlands,Springer Nature B.V
